04/13/2026
We are beggining recruitment for the AMAZE 8 trial investigating a new dual agent weight loss IP from Novo. The comparator is semaglutide (Wegovy). The trial is for people with type 2 diabetes treated with diet or pills who have a BMI of >27. You can not have been treated with a GLP-1 within the last year. If interested, please call our office at 301-770-7373.